AAO: Study confirms Phase III results for uveitis treatment

Video
Conference|AAO

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Related Content
Carbomer-containing gels from Aacarb, Aacomer and Puroptics could be at risk of contamination. Images courtesy of MHRA.

MHRA issues safety recall for dry eye gel treatments

November 28th 2023
Article

The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned

A researcher in personal protective equipment looks at a white rabbit in a glass tank. Image credit: ©Elnur – stock.adobe.com

Novel 3D-printed device may offer a new method to test pharmaceuticals

November 28th 2023
Article

Moving toward eliminating drug and chemical safety testing in animals

Rob Thornhill, CEO, Centricity Vision, at AAO 2023

AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill

November 28th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

A person holds a phone in their hand. Above the phone, icons such as a cross, a pill, a wheelchair and a syringe indicate they are looking at health information. Image credit: ©Monster Ztudio – stock.adobe.com

Harnessing digital media for enhanced patient engagement and outcomes

November 27th 2023
Article

Patients who received digital education demonstrated a better understanding of their disease and its management

Marco A. Zarbin, MD, PhD, Professor of Ophthalmology, Rutgers New Jersey Medical School

AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials

November 24th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

A photo of downtown London. Image credit: ©zgphotography – stock.adobe.com

MHRA issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI®)

November 13th 2023
Article

The company received marketing authorisation approval in the EU earlier this year

© 2023 MJH Life Sciences

All rights reserved.